The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
European leukemia net (ELN) 2013 response categories: Impact on clinical outcomes across four frontline tyrosine kinase inhibitor (TKI) modalities in chronic phase CML.
Preetesh Jain
No relevant relationships to disclose
Hagop M. Kantarjian
No relevant relationships to disclose
Dasarathula Jyothsna
No relevant relationships to disclose
Alfonso Quintas-Cardama
No relevant relationships to disclose
Elias Jabbour
No relevant relationships to disclose
Marylou Cardenas-Turanzas
No relevant relationships to disclose
Sara Dellasala
No relevant relationships to disclose
Sherry Pierce
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Susan Mary O'Brien
No relevant relationships to disclose
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva